FDA issues warning for compounded drugs from Cantrell Drug Company
Editor's Note
The Food & Drug Administration (FDA) on March 2 issued a warning for healthcare professionals not to use drug products produced by Cantrell Drug Company (Little Rock, Arkansas), including opioids and other drugs intended for sterile injections.
The FDA is concerned about serious deficiencies in Cantrell’s compounding operations, including processes to ensure quality and sterility assurance.
Posted 03/02/2018] AUDIENCE: Patient, Health Professional, Risk Manager ISSUE: FDA is alerting health care professionals and patients not to use drug products produced by Cantrell Drug Company of Little Rock, Arkansas, including opioid products and other drugs intended for sterile injection, that were produced by the company and distributed nationwide.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO